1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Hyperactivity, Motor in 6 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition the home cage behaviour of mice administered with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) using an acute dosing regimen was also investigated." | 1.33 | Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. ( Billinton, A; Brown, M; Chapman, H; Quinn, LP; Stean, TO; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Santoro, M | 1 |
| Fadda, P | 1 |
| Klephan, KJ | 1 |
| Hull, C | 1 |
| Teismann, P | 1 |
| Platt, B | 1 |
| Riedel, G | 1 |
| Ferguson, SA | 1 |
| Law, CD | 1 |
| Sarkar, S | 1 |
| Tan, LC | 1 |
| Protell, PH | 1 |
| Langston, JW | 1 |
| Togasaki, DM | 1 |
| Quinn, LP | 1 |
| Stean, TO | 1 |
| Chapman, H | 1 |
| Brown, M | 1 |
| Vidgeon-Hart, M | 1 |
| Upton, N | 1 |
| Billinton, A | 1 |
| Virley, DJ | 1 |
| Nicholas, AP | 1 |
| Arai, N | 1 |
| Isaji, M | 1 |
| Kojima, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
6 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Hyperactivity, Motor
| Article | Year |
|---|---|
Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Hyp | 2023 |
Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Hyp | 2015 |
The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Female; Hyperkinesis; L | 2002 |
Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Automation; Behavio | 2006 |
Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Disease Models, Animal; Dopamine | 2007 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 1996 |